利纳基巴特和潘布罗利祖马布在免疫检查点阻塞耐药的先进固体瘤中:一期1试验
Timothy A Yap1, Randy F Sweis2, Ulka Vaishampayan3
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TYap@mdanderson.org.
Nature medicine
|January 13, 2026
概括
新型抗潜伏转化生长因子-β1 (TGFβ1) 抗体Linavonkibart在癌症治疗中与pembrolizumab结合使用时显示出可管理的安全性. 这种组合在耐抗编程细胞死亡蛋白1 (PD-1) 治疗的患者中显示出有效性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗,但面临的挑战是耐药性,通常涉及转化生长因子-β1 (TGFβ1).
- 针对潜伏的TGFβ1提供了一种潜在的策略,以克服对抗编程细胞死亡蛋白1 (PD-1) 治疗的抗性.
研究的目的:
- 评估选择性抗潜伏TGFβ1抗体利纳基巴特的安全性,药理动力学,药理动力学和疗效.
- 评估先进癌症患者,特别是对PD-1抑制剂耐药的患者的利纳基巴特与潘布罗利祖马布的联合治疗.
主要方法:
- 一个多中心的,开放的,第一阶段的研究 (DRAGON试验) 涉及剂量升级和扩展队列.
- 患者接受了利纳基巴特作为单一药物或与pembrolizumab联合使用.
- 评估了安全性,耐受性,药理动力学,药理动力学和抗瘤活性.
主要成果:
- 利纳基巴特 (Linavonkibart) 显示出可管理的安全性,皮肤反应是主要的额外风险.
- 利纳基巴特和潘布罗利祖马布的组合通常与潘布罗利祖马布单一治疗的安全性一致.
- 抗PD-1耐药患者的客观应答率包括清细胞细胞癌 (ccRCC) 的20.0%,黑色素瘤的18.2%,头状细胞癌的9.1%,尿道癌的9.1%.
结论:
- 利纳基巴特单独使用或与潘布罗利祖马布 ( pembrolizumab) 结合使用是安全的和可以容忍的.
- 组合疗法在抗PD-1疗法耐药的患者中显示出有前途的抗瘤活性,特别是在ccRCC中.
- 生物标志物数据表明ccRCC的潜在患者选择策略.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


